The constitutive activation of Nrf2 has been described in many human cancers, while hyperactivation of the factor is shown to promote cell proliferation and metabolic reprogramming, as well as conferring cellular resistance to cancer therapies [63]. Here, NFE2L2 is linked to cancer.